<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00238290</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 23/03</org_study_id>
    <secondary_id>EU-20527</secondary_id>
    <nct_id>NCT00238290</nct_id>
  </id_info>
  <brief_title>Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer</brief_title>
  <official_title>Trastuzumab Monotherapy Followed By the Combination of Trastuzumab and Letrozole in Post-Menopausal Women With ER-Positive, HER-2 Positive Advanced Breast Cancer Resistant to a Nonsteroidal Aromatase Inhibitor: A Multicenter Two-Step Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different&#xD;
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and&#xD;
      help kill them or carry tumor-killing substances to them. Estrogen can cause the growth of&#xD;
      breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the&#xD;
      amount of estrogen the body makes. Giving trastuzumab together with letrozole after disease&#xD;
      progression may be an effective treatment for breast cancer.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving trastuzumab together with letrozole&#xD;
      works in treating postmenopausal women with progressive advanced breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the efficacy of trastuzumab (Herceptin®) monotherapy followed by trastuzumab&#xD;
           and letrozole in women with progressive advanced breast cancer that is resistant to&#xD;
           prior treatment with a nonsteroidal aromatase inhibitor.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the safety profile of this regimen in these patients.&#xD;
&#xD;
        -  Correlate HER-2-extracellular domain (ECD) levels with response to treatment in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the efficacy of this regimen in these patients.&#xD;
&#xD;
        -  Correlate response and time to tumor progression with changes in serum HER-2-ECD levels&#xD;
           in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once in weeks 1-3 OR once in&#xD;
      week 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable&#xD;
      toxicity. Patients experiencing disease progression after 9 weeks receive trastuzumab as&#xD;
      before and oral letrozole once daily in the absence of further disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 12 weeks until disease&#xD;
      progression and then at 6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30-40 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate as assessed by CT scan or MRI every 3 months</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression (TTP) every 3 months</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival every 3 months</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity every 3 months</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once in weeks 1-3 OR once in week 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression after 9 weeks receive trastuzumab as before and oral letrozole once daily in the absence of further disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab + Letrozole</intervention_name>
    <description>Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once in weeks 1-3 OR once in week 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression after 9 weeks receive trastuzumab as before and oral letrozole once daily in the absence of further disease progression or unacceptable toxicity.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed breast cancer&#xD;
&#xD;
               -  Advanced disease&#xD;
&#xD;
          -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion outside&#xD;
             previously irradiated areas that is ≥ 20 mm OR ≥ 10 mm if the slice thickness of the&#xD;
             CT scan or MRI is ≤ 5 mm&#xD;
&#xD;
               -  No nonmeasurable lesions as the only site of measurable disease, including any of&#xD;
                  the following:&#xD;
&#xD;
                    -  Osteoblastic bone metastases&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural or pericardial effusions&#xD;
&#xD;
                    -  Carcinomatous lymphangitis of the lung&#xD;
&#xD;
          -  Progressive disease after prior treatment with a nonsteroidal aromatase inhibitor&#xD;
             (e.g., letrozole or anastrozole) in an adjuvant or advanced disease setting&#xD;
&#xD;
          -  HER-2 amplification ≥ 2 by fluorescence in situ hybridization&#xD;
&#xD;
          -  No clinical symptoms or history of CNS or leptomeningeal metastases (no imaging is&#xD;
             required)&#xD;
&#xD;
          -  No visceral involvement with risk for organ dysfunction&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen receptor- and/or progesterone receptor-positive tumor&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Postmenopausal, defined by 1 of the following:&#xD;
&#xD;
               -  At least 55 years of age&#xD;
&#xD;
               -  Less than 55 years of age with spontaneous cessation of menses for ≥ 1 year&#xD;
&#xD;
               -  Less than 55 years of age with spontaneous cessation of menses within the past&#xD;
                  year, but amenorrheic with biochemical evidence of postmenopausal status&#xD;
&#xD;
               -  Underwent prior bilateral oophorectomy&#xD;
&#xD;
               -  Radiation or chemically induced menopause (treatment with luteinizing&#xD;
                  hormone-releasing hormone antagonists must continue during study treatment)&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT ≤ 2 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance &gt; 30 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No uncontrolled cardiac disease, including any of the following:&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Arrhythmia&#xD;
&#xD;
               -  Hypertension&#xD;
&#xD;
          -  No history of congestive heart failure&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  LVEF &gt; 50% by echocardiogram&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No severe dyspnea at rest&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated carcinoma in&#xD;
             situ of the cervix or localized nonmelanoma skin cancer&#xD;
&#xD;
          -  No psychiatric disability that would preclude study participation or giving informed&#xD;
             consent&#xD;
&#xD;
          -  No active autoimmune disease&#xD;
&#xD;
          -  No uncontrolled diabetes&#xD;
&#xD;
          -  No other serious underlying medical condition that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior trastuzumab (Herceptin®)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Prior neoadjuvant or adjuvant chemotherapy allowed&#xD;
&#xD;
          -  No prior palliative chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 1 month since prior experimental drugs on another clinical trial&#xD;
&#xD;
          -  No concurrent drugs that contraindicate study treatment&#xD;
&#xD;
          -  No other concurrent anticancer drugs&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dieter Koeberle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>CH-5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Claraspital AG</name>
      <address>
        <city>Basel</city>
        <zip>CH-4016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital-Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Bruderholz</name>
      <address>
        <city>Bruderholz</city>
        <zip>CH-4101</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Liestal</name>
      <address>
        <city>Liestal</city>
        <zip>CH-4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Beata Vergine</name>
      <address>
        <city>Mendrisio</city>
        <zip>CH-6850</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Beretta</name>
      <address>
        <city>Rheinfelden</city>
        <zip>CH-4310</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital Triemli</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Koeberle D, Ruhstaller T, Jost L, Pagani O, Zaman K, von Moos R, Oehlschlegel C, Crowe S, Pilop C, Thuerlimann B; Swiss Group for Clinical Cancer Research (SAKK). Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03). Endocr Relat Cancer. 2011 Mar 9;18(2):257-64. doi: 10.1530/ERC-10-0317. Print 2011 Apr.</citation>
    <PMID>21317203</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>October 12, 2005</study_first_submitted>
  <study_first_submitted_qc>October 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2005</study_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

